Companies with highest proportions of ties, and drugs in therapeutic area.

a<p>Analysis not possible for Cholesterol 2002, diabetes, GERD panels.</p><p>CKD, chronic kidney disease; n/a, not available.</p

Different ways to expand disease definitions.

<p>Different ways to expand disease definitions.</p

Conditions and characteristics of the panels and publications included in the study.

a<p>The same Mood Disorders work group proposed separate changes to bipolar and depression.</p>b<p>The cholesterol 2002 panel publication was silent on disclosure.</p>c<p>The COPD panel did not separate speaker and consultant ties.</p>d<p>The diabetes panel disclosed no ties.</p>e<p>GERD panel disclosures only pertained to one company and did not include separate categories.</p>f<p>The myocardial infarction panel reported ties in a method that did not allow categorization of different forms of tie.</p>g<p>The rheumatoid arthritis panel did not separate all speaker and consultant ties.</p><p>MI, myocardial infarction; MS, multiple sclerosis; n/a, not available; RA, rheumatoid arthritis.</p

Nature and extent of disclosed ties, by panel.

a<p>Individual members can disclose ties to more than one company.</p>b<p>Other = stock, employee, travel, royalties.</p>c<p>Non-industry ties include ties to public agencies, non-government organizations, and publishers; some disclosure sections did not include non-industry ties.</p>d<p>Disclosure sections lumped some categories together.</p><p>CKD, chronic kidney disease; IQR, interquartile range; MI, myocardial infarction; MS, multiple sclerosis; n/a, not available; RA, rheumatoid arthritis.</p

Flowchart identifying study conditions and panels reviewing definitions.

<p>Note: bipolar/depression was one panel.</p